HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

AbstractOBJECTIVE:
Evaluate and compare the effectiveness of CA125, HE4, Mesothelin and MMP7 marker levels to monitor ovarian cancer patients after surgery and chemotherapy. Evaluate the lead time of a rise of marker levels before recurrence.
METHODS:
The study consists of 23 patients with advanced stage ovarian/fallopian tube cancer. Blood was drawn after front line surgery and chemotherapy treatment and at 3 month intervals thereafter. One patient had chemoresistant disease, two patients remained in remission and 20 patients had recurring disease and were used for marker evaluation.
RESULTS:
In five patients HE4 was the only marker to elevate before recurrence with a lead time of up to 4½ months including one patient who did not have a CA125 response at all. In a further two patients, HE4 increased before CA125 did. In four of these seven patients, HE4 levels were consistently at or above threshold during remission when both CA125 and imaging results were negative. MMP7 elevated before recurrence in one patient who was negative for the other markers. Mesothelin elevated in two patients who were also positive for CA125 and HE4.
CONCLUSIONS:
HE4 can predict ovarian cancer recurrence earlier than CA125 and it can be elevated in patients that do not express CA125 at sufficient levels to make a clinical decision. MMP7 and Mesothelin have lower potential as markers for ovarian cancer recurrence to complement CA125. A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis.
AuthorsMichèl Schummer, Charles Drescher, Robin Forrest, Shirley Gough, Jason Thorpe, Ingegerd Hellström, Karl Erik Hellström, Nicole Urban
JournalGynecologic oncology (Gynecol Oncol) Vol. 125 Issue 1 Pg. 65-9 (Apr 2012) ISSN: 1095-6859 [Electronic] United States
PMID22155417 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • CA-125 Antigen
  • GPI-Linked Proteins
  • MUC16 protein, human
  • Membrane Proteins
  • Proteins
  • WAP Four-Disulfide Core Domain Protein 2
  • WFDC2 protein, human
  • MMP7 protein, human
  • Matrix Metalloproteinase 7
  • Mesothelin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (blood)
  • CA-125 Antigen (blood)
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • GPI-Linked Proteins (blood)
  • Humans
  • Matrix Metalloproteinase 7 (blood)
  • Membrane Proteins (blood)
  • Mesothelin
  • Middle Aged
  • Ovarian Neoplasms (blood, diagnosis, pathology, therapy)
  • Proteins (metabolism)
  • Recurrence
  • WAP Four-Disulfide Core Domain Protein 2

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: